Ambicin antimicrobial data

AMBI (Brooklyn) said it obtained positive data on its antimicrobial product from three institutional review board-approved human protocols, two in the U.K. and one in the U.S.

In microbiological evaluations, AMBI said the studies showed control of gram-negative anaerobes at least one log better than positive controls, including competitive products. The control of micro-flora was consistent with gingivitis studies in dogs, AMBI said. ...